Life sciences solutions and products provider Thermo Fisher Scientific (NYSE:TMO)’s shares have done well in September and are up by more than 8% since the 10th. On the 15th, Cramer discussed the strength in the shares in a conversation with his co-host David Faber amidst the turmoil in the AI sector on the back of worries about a slowdown:
“David, I think your conference is really important. Here’s why. I had Marc Fisher, the CEO of Thermo on, not that long ago. . .I’m sorry Marc Casper, I’ll tell you what bothered me, David. We’re sitting there talking about how strong business is. And Marc Casper’s really a titan in this. And no one was listening to him, no one. Not unlike when we had Beckton Dickinson on, no one was listening, and Cardinal Health, no one was listening. When I spoke to them behind the scene, what’s changed David? For making it so that everybody’s saying the same thing that they said three months ago and now we’re listening?
“I think that what’s happened is this that, when I speak to the executives off camera, when I do that, every time, I think they just felt that the rotation into all that stuff that yesterday people fled is so strong that the only place that they could really go to sell things, would be at, you would sell a Medtronic, you would sell a Thermo, you would sell out a Danaher.”
In line with what Cramer said, while Thermo Fisher Scientific’s shares have performed well recently, they were down by 25% from the start of the year until mid-May. However, while Cramer attributed the share performance to the need for investors to fund their AI investments, the broader debate for the firm is also in the context of the funding recovery in the biotechnology sector. For instance, at the Morgan Stanley healthcare conference on the 15th, Casper outlined that even “though funding wasn’t super strong, it was improving. But the confidence from our customers in the emerging biotech companies really was picking up. You saw funding start to improve as 2025 progressed. Has stepped up even further in 2026.”
This funding is crucial for Thermo Fisher Scientific since it kicks off investigations and drug research that eventually require the firm’s products. Early signs of the recovery were also present in the firm’s second quarter report, which saw it post 5% organic growth, which was the fastest since 2021. The organic growth, along with a 13% earnings growth in Q2, coupled with the funding recovery, were also part of UBS’s September coverage of Thermo Fisher Scientific, where the bank bumped the rating to Buy from Neutral and raised the share price target to $730 from $540. Yet, Deutsche Bank pointed to funding uncertainty when it downgraded the shares to Hold from Buy, joining the chorus of bears who point towards the funding’s cyclicality.
Looking at Becton, Dickinson and Company (NYSE:BDX), its forward P/E multiple of 12.27 is nearly half of TMO’s 23.58. Revenue growth for the fiscal third quarter at 5.4% was slower than TMO’s 10%, while organic growth of 4.4% was closer. On the costs front, Becton, Dickinson and Company (NYSE:BDX) did better through its higher adjusted operating margin of 24.9% comapred to TMO’s 22.8%. Yet, unlike TMO, for BDX, a key factor that has the bears worried is the firm’s troubles with the FDA for its Alaris system. Other regulatory troubles the firm has faced in 2026 include the recall of contaminated sodium chloride ampules and an FDA warning letter tracking a 3-week shipping hold on ChloraPrep and PurPrep products.
Looking at hedge fund sentiment, 46 hedge funds had held a stake in BDX during Q2, while the figure was 51 for TMO. Given BDX’s regulatory problems, the fact that its short interest as a percentage of float of 4.47% is higher than TMO’s 1.54% is unsurprising. Notable hedge fund exits from BDX in Q2 included Millennium Management and Two Sigma Advisors while Greenhaven Associates added an $859 million stake.
READ NEXT: Jim Cramer Draws the Line on NVIDIA in China: Why National Security Comes First and Jim Cramer Defends His Dell Stance as Investors Complain About Missing Out.
